<DOC>
	<DOCNO>NCT01371656</DOCNO>
	<brief_summary>This randomized phase III trial study well levofloxacin work prevent infection young patient acute leukemia receive chemotherapy undergoing stem cell transplant . Giving antibiotic may effective prevent control early infection patient receive chemotherapy undergoing stem cell transplant acute leukemia . It yet know whether levofloxacin effective preventing infection .</brief_summary>
	<brief_title>Levofloxacin Preventing Infection Young Patients With Acute Leukemia Receiving Chemotherapy Undergoing Stem Cell Transplantation</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether levofloxacin give prophylactically period neutropenia patient treat chemotherapy acute leukemia ( AL ) undergo hematopoietic stem cell transplantation ( HSCT ) decrease incidence bacteremia . SECONDARY OBJECTIVES : I . To determine effect prophylactic levofloxacin resistance pattern bacterial isolates sterile site culture , evolution antimicrobial resistance peri-rectal swab isolates Enterobacteriaceae , Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Streptococcus mitis . II . To determine effect levofloxacin prophylaxis total number day antibiotic administration ( prophylactic , empiric , treatment ) child undergo therapy AL HSCT . III . To determine whether levofloxacin prophylaxis reduces incidence fever neutropenia , severe infection , death bacterial infection . IV . To assess safety levofloxacin prophylaxis , specific attention musculoskeletal disorder include tendinopathy tendon rupture . V. To assess impact prophylactic levofloxacin incidence Clostridium difficile-associated diarrhea ( CDAD ) , incidence microbiologically document invasive fungal infection ( IFI ) . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive levofloxacin orally ( PO ) intravenously ( IV ) 60-90 minute daily ( QD ) twice daily ( BID ) begin day 3 2 consecutive course chemotherapy begin day -2 HSCT continue blood count recover . ARM II : Patients receive establish standard care receive chemotherapy HSCT patient Arm I . After completion study therapy , patient follow 1 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>Patient must fit 1 follow 2 category : Chemotherapy patient Planned receive least 2 consecutive cycle ( require first 2 cycle ) intensive chemotherapy either : De novo , relapse secondary acute myeloid leukemia ( AML ) , acute leukemia ambiguous lineage treat standard AML therapy Relapsed acute lymphoblastic leukemia ( ALL ) For purpose study , `` intensive chemotherapy '' define regimen predict local investigator cause neutropenia &gt; 7 day ; example include , limited , treatment `` 4drug induction '' ( anthracycline , vincristine , asparaginase , steroid ) , high dose cytarabine , anthracycline/cytarabine , ifosfamide/etoposide , clofarabinecontaining regimen Stem cell transplantation patient Planned receive least 1 myeloablative autologous allogeneic HSCT For purpose study , myeloablative autologous allogeneic HSCT condition regimen predict local Investigator cause neutropenia &gt; 7 day Creatinine clearance radioisotope glomerular filtration rate ( GFR ) &gt; 70 mL/min/1.73 m^2 OR serum creatinine base age/gender follow : 0.5 mg/dL ( 6 month &lt; 1 year age ) 0.6 mg/dL ( 1 &lt; 2 year age ) 0.8 mg/dL ( 2 &lt; 6 year age ) 1.0 mg/dL ( 6 &lt; 10 year age ) 1.2 mg/dL ( 10 &lt; 13 year age ) 1.5 mg/dL ( male ) /1.4 mg/dL ( female ) ( 13 &lt; 16 year age ) 1.7 mg/dL ( male ) /1.4 mg/dL ( female ) ( &gt; = 16 year age ) Patients must performance status correspond Eastern Cooperative Oncology Group ( ECOG ) score 0 , 1 , 2 ; use Karnofsky patient &gt; 16 year age Lansky patient = &lt; 16 year age All patient and/or parent legal guardian must sign write informed consent All institutional , Food Drug Administration ( FDA ) , National Cancer Institute ( NCI ) requirement human study must meet Patients previously enrol trial eligible ; therefore , patient AL study intensive chemotherapy eligible enrolled HSCT Patients allergy quinolones Patients chronic active arthritis Patients know pathologic prolongation correct QT ( QTc ) Females pregnant breast feeding Patients treat antibacterial agent , follow : Cotrimoxazole agent include dapsone , atovaquone , pentamidine administer Pneumocystitis jiroveci ( PCP ) prophylaxis Topical antibiotic Central venous catheter antibiotic lock therapy Note : prophylactic antifungal therapy NOT exclusion criterion Patients currently enrol ACCL1034 study eligible complete 90 day observation period study</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>